Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $12.60.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 13.5% and a 56.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $26.25 average price target, implying a 108.3% upside from current levels. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.40 and a one-year low of $8.61. Currently, Epizyme has an average volume of 442.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Develops therapeutics for the treatment of patients with genetically defined cancers